The Swiss drugmaker is paying China’s Abogen $575 million upfront for an injected mRNA that makes a B-cell-killing T-cell engager inside the patient — a possible simpler route to the “immune reset” that CAR-T promised for autoimmune disease.
The Autus valve can be widened with a balloon catheter as a child grows, from toddler size to adult size — sparing some children born with heart defects from repeated open-heart surgeries.
CAR-T turns a patient’s own immune cells into a living drug. It has transformed some blood cancers and is now being tested in lupus and multiple sclerosis. A plain-language guide to the process, the risks and what comes next.
From rheumatoid arthritis to eczema and alopecia, JAK inhibitors are among the most versatile drugs in immunology. A plain-language guide to how they work, the main ones, and why they carry a boxed warning.
With the $18 billion allergy and eczema blockbuster losing patent protection in 2031, the partners are betting on four long-acting antibodies that hit the same pathways with far fewer injections.
Bristol Myers Squibb’s heart drug becomes the first of its class approved for adolescents with the inherited condition, a leading cause of sudden cardiac death in young people.
The deal, worth up to $2.6 billion, gives Novo an early-stage oral GLP-1/GIP drug designed to be taken once a week — a bid to leapfrog today’s daily pills as its rivalry with Lilly intensifies.
Both remove amyloid from the brain and modestly slow early Alzheimer’s. They differ in how they are given, how long treatment lasts, the risk of brain swelling, and cost — differences that matter when choosing.
The drugmaker is buying a stake in the developer of the bispecific antibody that beat Keytruda in a lung cancer trial, and will test it alongside its antibody-drug conjugates in gastrointestinal cancers.
TrumpRx.gov lists discounted cash prices for brand-name drugs, including GLP-1s such as Zepbound, Wegovy and Ozempic. Here is how it works, what the prices are, and when it is — and isn’t — the cheapest option.
Children with idiopathic nephrotic syndrome have relied on steroids since the 1950s. Roche’s obinutuzumab is now approved to keep frequently relapsing patients in remission — offering a way off repeated steroid courses.
Tavapadon targets a narrower set of dopamine receptors than older drugs, aiming to ease movement symptoms with fewer of the side effects that make dopamine agonists hard to tolerate.